A
AN2 Therapeutics
Innovative small molecule therapeutics targeting infectious diseases and oncology using boron chemistry
About AN2 Therapeutics
AN2 Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics derived from its proprietary boron chemistry platform. The company is focused on addressing unmet medical needs in infectious diseases and oncology. AN2 Therapeutics is currently advancing a pipeline that includes epetraborole, an investigational drug aimed at treating Mycobacterium avium complex (MAC), the most common type of nontuberculous mycobacteria (NTM) lung disease. The company also has compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs targeting other infectious diseases and cancer. AN2 Therapeutics operates in the biopharmaceutical market, serving patients with serious and life-threatening conditions. Its business model involves obtaining non-dilutive funding from public and private agencies and foundations to advance its global health initiatives. The company generates revenue through the development and potential commercialization of its drug candidates, pending successful clinical trials and regulatory approvals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2019
- Headquarters
- Menlo Park, United States
- Listing
- IPO 2022
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 76.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VC✓Other financing | Mar 2026 | $40M | — | Coastlands Capital · Vivo Capital · Commodore Capital | ↗ |
| POST IPO EQUITY✓Other financing | Aug 2023 | $70M | — | Frazier Healthcare Partners · RA Capital Management · Marshall Wace · Avidity Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AN2 Therapeutics is 2.9K monthly website visits, up 0% over the last three months. AN2 Therapeutics's team grew 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Mountain Group Partners
RA Capital Management
BVF Partners
Monashee Investment Management
Surveyor Capital
Avidity Partners
Hatteras Venture Partners
Series B and later5 investors entered at this stage
Frazier Healthcare Partners
Marshall Wace
TCGX
Adage Capital
Janus Henderson Investors
Other known investors6 additional known investors
- CCCoastlands Capital
Commodore Capital
Vivo Capital
Adjuvant Capital- BVBioRock Ventures
Flucas Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AN2 Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AN2 Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.